SCHEDULE: Vanguard Group Reports 0% Stake in Tango Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Tango Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for Tango Therapeutics Inc. common stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of Tango Therapeutics Inc.'s Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc., which became effective on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group will report beneficial ownership separately, in accordance with SEC Release No. 34-39538.
• The Vanguard Group, Inc. (the parent entity) no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the potential for misinterpretation by the market regarding The Vanguard Group's overall investment in Tango Therapeutics, despite the explanation of an internal reporting realignment.

Negatives

• The Vanguard Group, as the parent entity, no longer reports a beneficial ownership stake in Tango Therapeutics Inc., which could be misinterpreted by some investors as a full divestment by Vanguard.

Risks

• Potential for misinterpretation by investors regarding The Vanguard Group's overall investment in Tango Therapeutics Inc. due to the 0% reported by the parent entity, despite the explanation of an internal reporting realignment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics Inc.'s operational or financial performance. It pertains solely to The Vanguard Group's beneficial ownership reporting structure.

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are not uncommon and typically reflect changes in internal reporting structures rather than a fundamental shift in investment strategy across all underlying funds. However, the immediate perception for the issuer, Tango Therapeutics, might be a reduction in institutional support if the nuance of disaggregated reporting is not fully understood by the market.

Comparison to Industry Standards

• This filing primarily reflects an internal reporting change by The Vanguard Group, rather than a performance-based assessment of Tango Therapeutics. Therefore, direct comparison to industry-specific company or project results is not applicable.
• The change aligns with SEC guidelines for disaggregated reporting by large investment groups, such as those followed by other major asset managers like BlackRock or State Street, when they undergo similar internal structural adjustments.

Stakeholder Impact

• Shareholders: May experience short-term negative sentiment if the change is misinterpreted as a full divestment by Vanguard, potentially leading to share price volatility.
• Investment Professionals: Will need to understand the nuance of Vanguard's internal realignment and disaggregated reporting to accurately assess the true level of institutional ownership by Vanguard-managed funds.

Key Dates

Recommendation

The filing primarily details an internal reporting realignment by The Vanguard Group, resulting in the parent entity reporting 0% beneficial ownership in Tango Therapeutics Inc. While this is not a direct divestment by all Vanguard funds, the immediate market perception could be negative. Without further information on Tango Therapeutics' operational performance or strategic outlook, a 'hold' recommendation is appropriate to assess market reaction and await more fundamental company news.

Keywords

Tango Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Investment Realignment